Doximity Q4 2026 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $145 million, up 5% year-over-year, exceeding guidance.

Full Year Revenue: $645 million, up 13% year-over-year.

Free Cash Flow: $107 million in Q4 (first-ever 9-digit quarter), $317 million for the full year, up 19% year-over-year.

Adjusted EBITDA Margin: 45% in Q4, 55% for the full year.

Net Revenue Retention Rate: 109% on a trailing 12-month basis; top 20 customers at 114%.

Customer Base: 125 customers contributing at least $500,000 in subscription revenue, accounting for 83% of total revenue.

2Strategic Updates and Business Highlights

AI Investment Year: Doximity is focusing heavily on AI, with nearly half of U.S. doctors using their AI tools. Engagement among prescribers increased by 30% year-over-year.

New Product Launches: Introduced ePrescribing and partnered with Aledade for value-based care AI agents.

Clinical AI Suite: 140 health systems have purchased this suite, including 7 of the top 20 hospitals.

Management Changes: Matt Sonefeldt appointed as new CFO, and Dr. Steve Zatz as President, bringing significant industry experience.

3Forward Guidance and Outlook

Q1 FY2027 Revenue Guidance: Expected between $151 million and $152 million (4% growth at midpoint).

Full Year FY2027 Revenue Guidance: Expected between $664 million and $676 million (4% growth at midpoint).

Adjusted EBITDA Guidance: Q1 expected between $68.5 million and $69.5 million; full year between $323 million and $335 million (49% adjusted EBITDA margin).

Stock-Based Compensation: Expected to increase to low 20s as a percentage of revenue in FY2027.

4Challenges and Points of Concern

Market Conditions: Short-term demand in the healthcare professional (HCP) digital pharma ad market is soft, with visibility limited due to policy uncertainty and macroeconomic risks.

AI Revenue Contribution: Minimal expected in FY2027 as the company invests heavily in AI capabilities, which may weigh on near-term margins.

Customer Spending Trends: Clients are opting for shorter-term commitments, leading to less revenue visibility and potential impacts on growth.

Competitive Pressures: Increased competition in the AI space and the need for regulatory approvals may slow monetization efforts.

5Notable Q&A Insights

AI Search Product: High interest from pharmaceutical companies in AI solutions; potential for a multibillion-dollar market.

Customer Spending Behavior: Clients are currently focused on innovation or low-cost options, impacting demand for traditional offerings.

Regulatory Environment: Ongoing regulatory concerns are affecting the pace of new product launches and client commitments.

Long-Term Growth Potential: Despite current challenges, Doximity remains optimistic about capturing market share and growing revenue as AI adoption increases. Overall, Doximity's Q4 2026 results reflect solid financial performance and a strong commitment to AI innovation, though they face challenges related to market conditions and competitive pressures. The company is positioning itself for long-term growth while navigating a cautious spending environment among clients.